5 Key Takeaways

• 1

  SGLT2 inhibitors were linked to lower risks of kidney, cardiovascular, and hepatic complications in patients with type 2 diabetes and cirrhosis.

• 2

  The study analyzed data from 24,259 patients, comparing outcomes between those treated with SGLT2 inhibitors and DPP-4 inhibitors.

• 3

  Patients treated with SGLT2 inhibitors had a significantly reduced risk of end-stage kidney disease and acute kidney injury.

• 4

  Major adverse cardiovascular events were less frequent in patients receiving SGLT2 inhibitors compared to those on DPP-4 inhibitors.

• 5

  Fewer hepatic decompensation events were observed in patients treated with SGLT2 inhibitors, suggesting potential benefits for this population.